InflaRx N.V. (IFRX)Healthcare | Biotechnology | Jena, Germany | NasdaqGS
2.23 USD
-0.04
(-1.762%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 2.20 -0.03 (-0.030%) ⇩ (Aug. 28, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 1:06 a.m. EDT
The investment case for InflaRx is currently bifurcated between optimistic analyst targets and a brutal historical reality. While the balance sheet appears robust with minimal debt and a massive cash reserve relative to obligations, the stock has suffered a catastrophic 97% decline over the last seven years, with the most recent two years showing consecutive negative annual returns. This multi-year structural deterioration suggests the market has priced in severe execution risks or pipeline failures that outweigh the potential of the drug assets. The absence of any dividend yield further limits the floor for investors. On the short end, the heavy put open interest indicates traders are hedging against further declines rather than betting on a reversal, keeping the immediate outlook neutral-to-bearish despite the 'strong buy' ratings which likely reflect the theoretical upside of the pipeline rather than current operational performance. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.123632 |
| AutoETS | 0.123636 |
| AutoTheta | 0.123994 |
| MSTL | 0.143193 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 35% |
| H-stat | 0.96 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.254 |
| Excess Kurtosis | -0.68 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.57 |
| Market Cap | 328,631,136 |
| Forward P/E | -5.53 |
| Beta | 2.52 |
| Website | https://www.inflarx.de |
As of Aug. 22, 2026, 1:06 a.m. EDT: Speculators are positioning heavily for downside protection, evidenced by significant open interest in out-of-the-money puts at strikes below the current price across multiple expirations. Conversely, call activity is sparse and concentrated deep in-the-money, suggesting a lack of speculative bullish momentum despite the company's 'strong buy' analyst consensus.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.27428567 |
| Address1 | Winzerlaer Str. 2 |
| All Time High | 53.1 |
| All Time Low | 0.711 |
| Ask | 2.9 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 1,104,760 |
| Average Daily Volume3 Month | 1,167,547 |
| Average Volume | 1,167,547 |
| Average Volume10Days | 1,104,760 |
| Beta | 2.515 |
| Bid | 1.67 |
| Bid Size | 2 |
| Book Value | 1.1561165 |
| City | Jena |
| Country | Germany |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.23 |
| Current Ratio | 8.218 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 2.37 |
| Day Low | 2.21 |
| Debt To Equity | 0.57 |
| Display Name | InflaRx |
| Earnings Call Timestamp End | 1,778,160,600 |
| Earnings Call Timestamp Start | 1,778,160,600 |
| Earnings Timestamp | 1,786,019,400 |
| Earnings Timestamp End | 1,794,227,400 |
| Earnings Timestamp Start | 1,794,227,400 |
| Ebitda | -35,641,328 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -4.796 |
| Enterprise To Revenue | -16,924.049 |
| Enterprise Value | 170,949,824 |
| Eps Current Year | -0.266 |
| Eps Forward | -0.4031592 |
| Eps Trailing Twelve Months | -0.57 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.9791 |
| Fifty Day Average Change | 0.25090003 |
| Fifty Day Average Change Percent | 0.12677482 |
| Fifty Two Week Change Percent | 27.428568 |
| Fifty Two Week High | 2.949 |
| Fifty Two Week High Change | -0.71899986 |
| Fifty Two Week High Change Percent | -0.24381143 |
| Fifty Two Week Low | 0.798 |
| Fifty Two Week Low Change | 1.432 |
| Fifty Two Week Low Change Percent | 1.7944863 |
| Fifty Two Week Range | 0.798 - 2.949 |
| Financial Currency | EUR |
| First Trade Date Milliseconds | 1,510,065,000,000 |
| Float Shares | 98,114,814 |
| Forward Eps | -0.4031592 |
| Forward P E | -5.531314 |
| Free Cashflow | -4,312,136 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 65 |
| Fullday Change | -0.04 |
| Fullday Change Percent | -1.76211 |
| Fullday Price | 2.2 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -4,868,845 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.02948 |
| Held Percent Institutions | 0.70342004 |
| Implied Shares Outstanding | 147,368,221 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinical trial for the treatment for patients suffering from early septic organ dysfunction, biological proof of concept was established, demonstrating its unique C5a blocking ability and selectivity; Izicopan, an oral, low molecular weight drug to target C5aR with high affinity and selectivity has completed completing Phase 2a trials; and IFX002, an advancement of vilobelimab technology, which is in preclinical development for the treatment of chronic inflammatory indications. It has co-development agreement with Staidson (Beijing) BioPharmaceuticals Co., Ltd.; Cell line sales agreement with Catalent Pharma Solutions LLC; Clinical Trial Collaboration Agreement with the U.S. DHHSs, Administration for Strategic Preparedness and Response (ASPR), BARDA and PPD Development, L.P., or PPD. InflaRx N.V. was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. The company was founded in 2007 and is headquartered in Jena, Germany. |
| Long Name | InflaRx N.V. |
| Market | us_market |
| Market Cap | 328,631,136 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_42434000 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -39,144,616 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 333,052,179 |
| Number Of Analyst Opinions | 8 |
| Open | 2.28 |
| Operating Cashflow | -23,709,786 |
| Operating Margins | 3,529.65 |
| Payout Ratio | 0.0 |
| Phone | 49 3641 508 180 |
| Post Market Change | -0.029999971 |
| Post Market Change Percent | -1.3452902 |
| Post Market Price | 2.2 |
| Post Market Time | 1,787,959,805 |
| Previous Close | 2.27 |
| Price Eps Current Year | -8.383459 |
| Price Hint | 4 |
| Price To Book | 1.9288714 |
| Price To Sales Trailing12 Months | -32,534.516 |
| Profit Margins | 0.0 |
| Quick Ratio | 7.953 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.04 |
| Regular Market Change Percent | -1.76211 |
| Regular Market Day High | 2.37 |
| Regular Market Day Low | 2.21 |
| Regular Market Day Range | 2.21 - 2.37 |
| Regular Market Open | 2.28 |
| Regular Market Previous Close | 2.27 |
| Regular Market Price | 2.23 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 610,389 |
| Return On Assets | -0.18541999 |
| Return On Equity | -0.38522997 |
| Revenue Per Share | -0.0 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 147,368,221 |
| Shares Percent Shares Out | 0.0642 |
| Shares Short | 9,464,470 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 8,877,421 |
| Short Name | InflaRx N.V. |
| Short Percent Of Float | 0.07 |
| Short Ratio | 10.05 |
| Source Interval | 15 |
| Symbol | IFRX |
| Target High Price | 14.077638 |
| Target Low Price | 3.0162225 |
| Target Mean Price | 7.916432 |
| Target Median Price | 8.5382395 |
| Total Cash | 158,514,496 |
| Total Cash Per Share | 1.076 |
| Total Debt | 833,179 |
| Total Revenue | -10,101 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.57 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.4858 |
| Two Hundred Day Average Change | 0.7442 |
| Two Hundred Day Average Change Percent | 0.50087494 |
| Type Disp | Equity |
| Volume | 610,389 |
| Website | https://www.inflarx.de |
| Zip | 7,745 |